SELLAS Life Sciences Group (SLS) Equity Ratio: 2011-2024
Historic Equity Ratio for SELLAS Life Sciences Group (SLS) over the last 9 years, with Sep 2024 value amounting to 0.60.
- SELLAS Life Sciences Group's Equity Ratio rose 226.69% to 0.60 in Q3 2024 from the same period last year, while for Sep 2024 it was 0.60, marking a year-over-year increase of 226.69%. This contributed to the annual value of -1.28 for FY2023, which is 653.70% down from last year.
- According to the latest figures from Q3 2024, SELLAS Life Sciences Group's Equity Ratio is 0.60, which was up 211.20% from 0.19 recorded in Q2 2024.
- In the past 5 years, SELLAS Life Sciences Group's Equity Ratio registered a high of 0.77 during Q4 2021, and its lowest value of -1.28 during Q4 2023.
- Its 3-year average for Equity Ratio is 0.15, with a median of 0.26 in 2023.
- Per our database at Business Quant, SELLAS Life Sciences Group's Equity Ratio plummeted by 653.70% in 2023 and then spiked by 226.69% in 2024.
- SELLAS Life Sciences Group's Equity Ratio (Quarterly) stood at 0.61 in 2020, then increased by 27.53% to 0.77 in 2021, then plummeted by 70.09% to 0.23 in 2022, then slumped by 653.70% to -1.28 in 2023, then spiked by 226.69% to 0.60 in 2024.
- Its last three reported values are 0.60 in Q3 2024, 0.19 for Q2 2024, and 0.40 during Q1 2024.